The trials of Oxford University-developed vaccine resumed after getting nod from British regulators.

"Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so," the company's statement read as quoted by the media.

The Oxford Vaccine trial was on Wednesday halted after a suspected serious adverse reaction was seen in a participant in the United Kingdom.

The nature of the suspected serious adverse reaction was not immediately known. 

India's Serum Institute of India (SII) on Thursday also halted the Oxford vaccine trials in the country, but of course after being pulled up by the Drugs Controller General of India (DCGI).

The central drug regulator had pulled up the Serum Institute for not informing about the pause of vaccine trials in other nations.